Physician profile
Ron D Lee
NPI 1376572800
$8,974.85
in general payments reported to CMS, 2019-2025
39 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,316 · 2020: $1,530 · 2021: $1,816 · 2022: $1,314 · 2023: $1,084 · 2024: $897 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,938 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,937.91 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,325.43 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $937.90 | 2020-2025 | |
| Novo Nordisk INC | $823.86 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $745.85 | 2019-2025 | |
| Amgen INC. | $592.52 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $567.21 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $545.83 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $508.76 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.20 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $332.50 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $257.76 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $251.47 | 2019-2022 | |
| Allergan, INC. | $214.63 | 2019-2020 | |
| Esperion Therapeutics, INC. | $210.79 | 2020-2022 | |
| Astellas Pharma US INC | $203.25 | 2019-2024 | Veozah |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.